Back to UBS Group AG UBS Group AG

ELDNELDN
Showing 8 of 22 quarters

Position history for UBS Group AGUBS Group AG's holdings in ELEDON PHARMACEUTICALS INC

UBS Group AG holds 1M shares of ELDN (ELEDON PHARMACEUTICALS INC), worth $4.1M as of 2026-Q2. The position was increased (+91.5% shares). ELDN represents 0.0% of UBS Group AG's portfolio.

Current Value

$4.1M

Current Shares

1M

Total Value Change

+$4.1M

Total Shares Change

+1M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1M
+91.5%
$4.1M0.0%$3.94
42
2026-Q1
Decreased
547,447
-7.7%
$1.7M0.0%$2.50
0
2025-Q4
Increased
593,131
+534.7%
$895,6280.0%$1.51
40
2025-Q3
Decreased
93,453
-26.0%
$242,0430.0%$2.54
0
2025-Q2
Increased
126,266
+443.7%
$342,1810.0%$2.69
38
2025-Q1
Decreased
23,225
-92.7%
$78,7340.0%$3.35
0
2024-Q4
Increased
318,581
+79.6Kx
$1.3M0.0%$4.14
41
2024-Q3
Decreased
4
-100.0%
$100.0%$2.49
0

Other major holders of ELDN: BlackRock, Inc., RA CAPITAL MANAGEMENT, L.P., VANGUARD CAPITAL MANAGEMENT LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used